Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
RL
Relmada Therapeutics, Inc. Common Stock
RLMD
Mkt Cap
$331.2M
Volume
949.80K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
RL
RLMD
RL
Relmada Therapeutics, Inc. Common Stock
RLMD
News
·
Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
Mkt Cap
$341.3M
Volume
949.80K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Insider
Filings
Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
Relmada Therapeutics announced that senior management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference in Boston (September 8-10, 2026). The company is advancing its lead candidates NDV-01 and sepranolone through clinical development, with NDV-01 expected to reach IND filing by year-end 2026 and a Phase 3 RESCUE registrational program planned for initiation.
GlobeNewswire Inc. · Sep 1, 2026
Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes
Relmada Therapeutics, a clinical-stage biotechnology company, announced its addition to the Russell 2000® and Russell 3000® Indexes effective June 26, 2026. The company's CEO attributed the achievement to robust 12-month data for its lead candidate NDV-01 in NMIBC treatment and a well-capitalized balance sheet.
GlobeNewswire Inc. · Jun 29, 2026
Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026
Relmada Therapeutics announced presentations of NDV-01 clinical data at the American Urology Association conference in May 2026. Phase 2 data showed a 76% complete response rate at 12 months in high-risk non-muscle invasive bladder cancer patients. The company's Phase 3 'RESCUE' registrational program remains on track for mid-2026 initiation.
GlobeNewswire Inc. · May 5, 2026
Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026
Relmada Therapeutics announced a conference call scheduled for March 19, 2026 at 4:30 PM ET to discuss fourth quarter 2025 financial results and business progress. The clinical-stage biotechnology company is also presenting at the Leerink Partners Global Healthcare Conference and recently completed an oversubscribed $160 million private placement financing.
GlobeNewswire Inc. · Mar 12, 2026
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
The psychedelic medicine sector is advancing with regulatory momentum, as the first psilocybin compound achieved two positive Phase 3 results in treatment-resistant depression. The DEA increased its 2026 psilocybin production quota by 67%. Five companies—Helus Pharma, Compass Pathways, Relmada Therapeutics, Alto Neuroscience, and Axsome Therapeutics—are progressing clinical programs targeting depression, anxiety, cognitive impairment, bladder cancer, and Alzheimer's agitation.
Benzinga · Feb 26, 2026
Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Relmada Therapeutics strengthens its clinical advisory board by appointing Dr. Yair Lotan as Clinical Advisory Board Chair and Dr. Raj S. Pruthi as CMO-Urology, supporting the development of their NDV-01 program with a planned Phase 3 trial in H1 2026.
GlobeNewswire Inc. · Jul 31, 2025
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025
Relmada Therapeutics announced positive Phase 2 data for its investigational drug NDV-01 in patients with high-grade non-muscle invasive bladder cancer. The data showed strong clinical activity and favorable tolerability, supporting further development of NDV-01.
GlobeNewswire Inc. · Apr 28, 2025
UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025
Relmada Therapeutics announced the presentation of an abstract at the American Urology Association (AUA2025) conference, highlighting the results of a prospective open-label study evaluating the safety and efficacy of their investigational drug NDV-01 for high-risk non-muscle invasive bladder cancer (HG-NMIBC).
GlobeNewswire Inc. · Apr 27, 2025
Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight
The depression treatment market is experiencing steady growth, driven by rising mental health awareness, increasing prevalence of depression, and advancements in novel therapies. The market is expanding with the introduction of innovative antidepressants, psychedelic-based treatments, and digital therapeutics.
GlobeNewswire Inc. · Feb 25, 2025
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Relmada Therapeutics announced the discontinuation of its Reliance II and Relight Phase 3 studies for REL-1017 due to recent data monitoring committee evaluation. The company will continue to advance the Phase 1 study of REL-P11 and explore strategic alternatives to maximize shareholder value.
Benzinga · Dec 9, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
RL
RLMD
Relmada Therapeutics, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
RLMD
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any RLMD yet.
Related Tickers
Earnings